To include your compound in the COVID-19 Resource Center, submit it here.

Ponatinib: Additional Phase I data

Data from a subset of 12 patients with acute myelogenous leukemia (AML) in an open-label, dose-escalation, U.S. Phase I trial

Read the full 200 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE